Four New MOTS-c Papers. Only One Measured People, and It Was a Snapshot.

MOTS-c is a 16-amino-acid peptide that is unusual for where its instructions are stored: not in the cell nucleus, like most proteins, but in the small separate genome inside mitochondria, the structures that produce most of a cell's energy. Peptides made this way are called mitochondrial-derived peptides. MOTS-c has drawn attention because laboratory work links it to AMPK, an enzyme that acts as a cell's energy sensor.

In October 2026, four new papers on MOTS-c entered PubMed. Read together, they show how the field currently looks: active, mechanistically interesting, and almost entirely preclinical. Here is what each one measured.

The human study: a cross-sectional snapshot of 30 men

A team writing in Antioxidants measured the amount of MOTS-c naturally circulating in the blood of 30 healthy men aged 18 to 25, split into three groups of ten: elite track-and-field athletes, recreationally active men and sedentary men. Nobody was given anything. The study simply measured what was already there.

Serum MOTS-c was highest in the athletes (about 508 picograms per millilitre), lower in the active group (about 440) and lowest in the sedentary group (about 319). It correlated strongly with VO2max, a standard measure of aerobic fitness, with an antioxidant enzyme called superoxide dismutase, and inversely with malondialdehyde, a marker of oxidative damage measured after exercise. Grip strength showed no significant correlation.

The authors state the main limitation themselves: the cross-sectional design precludes causal inference. A cross-sectional study takes one measurement at one point in time. It cannot tell whether fitter people make more MOTS-c, whether MOTS-c contributes to fitness, or whether both follow from something else. With ten people per group, all young men, the findings also cannot be generalised to women, older adults or people with illness.

This is also a study of the body's own MOTS-c. It says nothing about what happens when the peptide is supplied from outside.

The kidney study: diabetic mice and a human cell line

In Biochemical Pharmacology, researchers studied db/db mice, a strain bred to develop diabetes and diabetic kidney damage, alongside HK-2 cells, a laboratory line of human kidney tubule cells.

In the mice, MOTS-c was associated with lower urinary albumin-to-creatinine ratio (a marker of kidney damage), with the effect larger at higher amounts, and with less tubular injury, less fat build-up in kidney tissue and fewer markers of cellular ageing. The authors traced this to a protein called LARS1: MOTS-c lowered it, which freed up lipophagy, the process cells use to break down stored fat droplets. When the researchers forced HK-2 cells to overproduce LARS1, or blocked autophagy in the mice with a drug, the protective pattern largely disappeared.

That is a well-built mechanistic study, with the experiments run in both directions. It is still a mouse model and a cell line. Diabetic kidney disease in people develops over years, and no human kidney data were collected.

The fertility study: cells in a dish and mouse eggs

In Reproduction & Fertility, a team tested MOTS-c on granulosa cells, the support cells that surround a developing egg, using a human granulosa cell line made to mimic ageing, and on eggs taken from young and aged mice and treated outside the body.

In the cell line, MOTS-c was associated with greater mitochondrial mass and higher energy-linked respiration without a rise in reactive oxygen species. In the aged mouse eggs, treatment was associated with a higher rate of maturation, though results stayed below those of eggs from young mice.

The authors' own plain-language summary is unusually direct: the findings are from laboratory and animal experiments, not from women, and the study did not test fertilization, embryo development or live birth.

The computer study: a prediction, not an experiment

The fourth paper, in Frontiers in Immunology, analysed gene-activity data from a mouse model of radiation damage to the rectum and identified a group of immune cells linked to scarring. Using molecular docking, a computer simulation of how two molecules might fit together, it ranked MOTS-c as a top candidate to bind a protein on those cells.

No MOTS-c was tested on any cell or animal in that paper. The authors describe their proposal as pending experimental validation. A docking score is a hypothesis about shape, not evidence of an effect.

What has not been studied

• No published randomised, controlled human trial of MOTS-c given from outside the body appears among these papers.
• How supplied MOTS-c is absorbed, distributed and cleared in people has not been reported in any of them.
• Long-term human safety has not been characterised.
• None of the three experimental papers was an independent replication of an earlier finding.

What to watch

The evidence these October papers cannot supply is a registered, controlled human trial: participants randomly assigned to MOTS-c or placebo, with neither they nor the investigators knowing which, and an outcome that matters measured at the end. We will report one when it is published.

---

Correction, 2026-11-05. An earlier version of this article described a specific Phase 2a trial of MOTS-c (ClinicalTrials.gov record NCT07505745, "MOTS-MET") as underway, and cited that record as a source. We have removed that passage and the citation.

On review, that record belongs to a group of four registry entries filed by the same sponsor, all listing the same single hospital, the same contact, near-identical start dates and the same primary completion date, across four unrelated conditions. One of the four states in its own summary that it is a fictional example of a registry-style record. We cannot treat the remaining entries in that group as evidence that a real trial is recruiting, so we should not have reported one as fact.

A registry entry is a filing, not a verified study. We are adding a check on sponsor and site plausibility before citing any registry record in future.

Sources

1. Zhang Z, et al. Associations of Serum MOTS-c with Exercise Capacity and Antioxidant Markers in Young Males: A Cross-Sectional Study. Antioxidants (2026)
2. Wang J, et al. Mots-c attenuates diabetic nephropathy by downregulating LARS1 to promote lipophagy and suppress tubular senescence. Biochemical Pharmacology (2026)
3. Tsui KH, et al. The mitochondrial-derived peptide MOTS-c improves bioenergetics in aging-associated granulosa cells and oocytes. Reproduction & Fertility (2026)
4. Wang P, et al. Integrative transcriptomic and computational analysis associates Ms4a6c+ macrophages with fibrosis in radiation proctitis and computationally nominates MOTS-c as a candidate modulator. Frontiers in Immunology (2026)

Compounds in this article

MOTS-C